S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?

Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

$11.32
+0.12 (+1.07%)
(As of 03/28/2024 ET)
Today's Range
$10.80
$11.50
50-Day Range
$10.95
$16.62
52-Week Range
$3.00
$17.79
Volume
499,206 shs
Average Volume
1.12 million shs
Market Capitalization
$633.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Olema Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
85.5% Upside
$21.00 Price Target
Short Interest
Bearish
9.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$616,000 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.24) to ($2.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.11 out of 5 stars

Medical Sector

596th out of 938 stocks

Pharmaceutical Preparations Industry

266th out of 417 stocks

OLMA stock logo

About Olema Pharmaceuticals Stock (NASDAQ:OLMA)

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

OLMA Stock Price History

OLMA Stock News Headlines

OLMA Jul 2024 12.500 call
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
OLMA Apr 2024 22.500 call
OLMA Oct 2024 25.000 call
OLMA Oct 2024 10.000 put
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
OLMA Mar 2024 20.000 call
OLMA Mar 2024 10.000 put
See More Headlines
Receive OLMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/09/2023
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OLMA
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$28.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+85.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-96,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.61 per share

Miscellaneous

Free Float
42,775,000
Market Cap
$633.01 million
Optionable
Optionable
Beta
2.13
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Sean P. Bohen M.D. (Age 57)
    Ph.D., President, CEO & Director
    Comp: $1M
  • Mr. Shane William Charles Kovacs M.B.A. (Age 50)
    Chief Operating & Financial Officer
    Comp: $726.17k
  • Dr. Naseem Zojwalla M.D. (Age 51)
    Chief Medical Officer
    Comp: $775.48k
  • Mr. Geoffrey Mogilner
    Vice President of Investor Relations & Communications
  • Ms. Julie Dexter
    Senior VP & Head of People
  • Dr. David C. Myles Ph.D. (Age 61)
    Chief Discovery & Non-Clinical Development Officer
    Comp: $200k
  • Ms. Demiana Faltaos Ph.D.
    Pharm.D., VP & Head of Clinical Pharmacology
  • Mr. John B. Moriarty Jr. (Age 56)
    J.D., Corporate Secretary
    Comp: $434.32k
  • Ms. Sasha Austin CPA
    VP of Finance & Controller

OLMA Stock Analysis - Frequently Asked Questions

Should I buy or sell Olema Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OLMA shares.
View OLMA analyst ratings
or view top-rated stocks.

What is Olema Pharmaceuticals' stock price target for 2024?

7 analysts have issued 12-month price objectives for Olema Pharmaceuticals' stock. Their OLMA share price targets range from $18.00 to $28.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 85.5% from the stock's current price.
View analysts price targets for OLMA
or view top-rated stocks among Wall Street analysts.

How have OLMA shares performed in 2024?

Olema Pharmaceuticals' stock was trading at $14.03 at the beginning of the year. Since then, OLMA stock has decreased by 19.3% and is now trading at $11.32.
View the best growth stocks for 2024 here
.

When is Olema Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our OLMA earnings forecast
.

How were Olema Pharmaceuticals' earnings last quarter?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) released its earnings results on Thursday, March, 9th. The company reported ($0.65) EPS for the quarter, hitting the consensus estimate of ($0.65).

When did Olema Pharmaceuticals IPO?

Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering (IPO) on Thursday, November 19th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO.

Who are Olema Pharmaceuticals' major shareholders?

Olema Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.91%), Vanguard Group Inc. (4.91%), Dimensional Fund Advisors LP (3.11%), First Light Asset Management LLC (1.15%), Victory Capital Management Inc. (1.13%) and Perceptive Advisors LLC (0.98%). Insiders that own company stock include Biocapital Advisors L Paradigm, Bvf Partners L P/Il, Cyrus Harmon, David C Myles, G Walmsley Graham, Kinney Horn, Naseem Zojwalla and Sean Bohen.
View institutional ownership trends
.

How do I buy shares of Olema Pharmaceuticals?

Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OLMA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners